| RESEARCH ARTICLE
|Year : 2014 | Volume
| Issue : 1 | Page : 24-28
Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial
Arijit Ghosh1, Nilanjan Sengupta2, Pranab Sahana2, Debasis Giri2, Parama Sengupta1, Nina Das1
1 Department of Pharmacology, Nilratan Sircar Medical College, Kolkata, West Bengal, India
2 Department of Endocrinology, Nilratan Sircar Medical College, Kolkata, West Bengal, India
Objective: To compare the effectiveness and safety of add on therapy of bromocriptine with metformin in type 2 diabetes mellitus (DM) patients.
Material and Methods: Adult type 2 DM patients fulfilling the inclusion criteria were randomized in three groups. Group A received metformin (1000 mg/ day), while group B patients were treated with metformin (1000 mg/day) plus bromocriptine (0.8 mg/day) and group C received metformin (1000 mg/day) plus bromocriptine (1.6 mg/day) for 12 weeks. Fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), and body weight were measured at week 4, 8, and 12 visits and glycosylated hemoglobin (HbA 1C ) at week 12 visit.
Results: Metformin alone and in combination with bromocriptine in escalating dose (0.8 mg/day and 1.6 mg/day) significantly (P < 0.05) decreased FPG and PPPG levels at weeks 4, 8, and 12 compared with pretreatment values. HbA 1C level in all three treatment groups significantly (P < 0.05) decreased at week 12 as compared with pretreatment baseline value. HbA 1C level in groups B and C significantly (P < 0.05) decreased as compared with group A at week 12 . Addition of bromocriptine to metformin also significantly (P < 0.05) decreased FPG and PPPG levels in a dose-dependent manner as compared with metformin alone. Intergroup analysis did not show any statistically significant change in weight of study subjects at different intervals.
Conclusion: The combination of bromocriptine with metformin significantly decreased FPG, PPPG, and HbA 1C compared with metformin alone in type 2 DM patients in a dose-dependent manner.
Department of Pharmacology, Nilratan Sircar Medical College, Kolkata, West Bengal
Source of Support: None, Conflict of Interest: None
Clinical trial registration CTRI/2012/05/002659
[FULL TEXT] [PDF]*